Skip to main content
Erschienen in: Medical Oncology 2/2013

01.06.2013 | Original Paper

Application of five prognostic survival scores to primary myelofibrosis in 62 Brazilian patients

verfasst von: M. C. Souza, C. A. Rodrigues, M. R. R. Silva, J. Ribeiro, R. Tognon, F. A. Castro, B. P. Simões, E. X. Souto, M. L. Chauffaille

Erschienen in: Medical Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Primary myelofibrosis (PM) is a Philadelphia-negative clonal hematopoietic stem cell disorder characterized by intense reactive changes of bone marrow stroma with collagen fibrosis, osteosclerosis and angiogenesis. PM usually affects elderly people, and approximately half of the patients present JAK2V617F mutation. PM clinical course varies from 1 to 30 years, evolving from asymptomatic into progressive bone marrow failure, symptomatic splenomegaly or acute leukemia in 10–20 % of cases. PM risk stratification is based on parameters predicting survival, and several attempts have been made to identify clinical and laboratory features that could predict PM patient survival. This study applied five prognostic scores: Dupriez, Cervantes, Mayo, IPSS and DIPSS-Plus in 62 Brazilians patients from three centers, and compared their relevance and clinical usefulness considering the scores’ parameters, fibrosis, JAK2V617F mutation, splenomegaly, hepatomegaly and treatment. According to the Cervantes, Dupriez and Mayo scores, most patients were stratified into low-risk group. However, when IPSS and DIPSS-Plus were applied, most patients were classified into an intermediate range, being low risk in only 11 and 13 % of patients, respectively. Overall survival at 4 years was 84 %. The Cervantes score was the only one that remained significantly associated with survival in a multivariate analysis. In conclusion, the Cervantes score remains important to the prognostication of PM.
Literatur
1.
Zurück zum Zitat Chauffaille ML. Alterações cromossômicas em síndrome mielodisplásica. Rev Bras Hematol Hemoter. 2006;28(3):182–7. Chauffaille ML. Alterações cromossômicas em síndrome mielodisplásica. Rev Bras Hematol Hemoter. 2006;28(3):182–7.
2.
Zurück zum Zitat Santos LC, Chauffaille ML, Ribeiro JC, Silva NP, Cerutti J, Silva MR. Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia. Rev Bras Hematol Hemoter. 2011;33(6):417–24.PubMedCrossRef Santos LC, Chauffaille ML, Ribeiro JC, Silva NP, Cerutti J, Silva MR. Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia. Rev Bras Hematol Hemoter. 2011;33(6):417–24.PubMedCrossRef
3.
Zurück zum Zitat Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895–901.PubMedCrossRef Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895–901.PubMedCrossRef
5.
Zurück zum Zitat Cervantes F, Pereira A. Prognostication in primary myelofibrosis. Curr Hematol Malig Rep. 2012;7(1):43–9.PubMedCrossRef Cervantes F, Pereira A. Prognostication in primary myelofibrosis. Curr Hematol Malig Rep. 2012;7(1):43–9.PubMedCrossRef
6.
Zurück zum Zitat Helbig G, Wieczorkiewicz A, Woźniczka K, Wiśniewska-Piąty K, Rusek A, Kyrcz-Krzemień S. The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis. Med Oncol. 2012;29(4):2379–84. Helbig G, Wieczorkiewicz A, Woźniczka K, Wiśniewska-Piąty K, Rusek A, Kyrcz-Krzemień S. The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis. Med Oncol. 2012;29(4):2379–84.
7.
Zurück zum Zitat Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G, Einsele H, Gaspar HB, Gratwohl A, Passweg J, Peters C, Rocha V, Saccardi R, Schouten H, Sureda A, Tichelli A, Velardi A, Niederwieser D. European group for blood and marrow transplantation. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 2010;45(2):219–34.PubMedCrossRef Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G, Einsele H, Gaspar HB, Gratwohl A, Passweg J, Peters C, Rocha V, Saccardi R, Schouten H, Sureda A, Tichelli A, Velardi A, Niederwieser D. European group for blood and marrow transplantation. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 2010;45(2):219–34.PubMedCrossRef
8.
Zurück zum Zitat Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88(3):1013–8.PubMed Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88(3):1013–8.PubMed
9.
Zurück zum Zitat Cervantes F, Barosi G, Demory JL, Reilly J, Guarnone R, Dupriez B, Pereira A, Montserrat E. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102(3):684–90.PubMedCrossRef Cervantes F, Barosi G, Demory JL, Reilly J, Guarnone R, Dupriez B, Pereira A, Montserrat E. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102(3):684–90.PubMedCrossRef
10.
Zurück zum Zitat Tefferi A, Huang J, Schwager S, Li CY, Wu W, Pardanani A, Mesa RA. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer. 2007;109(10):2083–8.PubMedCrossRef Tefferi A, Huang J, Schwager S, Li CY, Wu W, Pardanani A, Mesa RA. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer. 2007;109(10):2083–8.PubMedCrossRef
11.
Zurück zum Zitat Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Cazzola M, Tefferi A. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010;116(15):2857–8.PubMedCrossRef Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Cazzola M, Tefferi A. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010;116(15):2857–8.PubMedCrossRef
12.
Zurück zum Zitat Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–7.PubMedCrossRef Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–7.PubMedCrossRef
13.
Zurück zum Zitat Elliott MA, Verstovsek S, Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res. 2007;31(11):1503–9.PubMedCrossRef Elliott MA, Verstovsek S, Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res. 2007;31(11):1503–9.PubMedCrossRef
14.
Zurück zum Zitat Vardiman JW, Brunning RD, Harris NL. WHO histological classification of chronic myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, et al., editors. World Health Organization classification of tumors: tumours of the haematopoietic and lymphoid tissues. Lyon: France, International Agency for Research on Cancer Press; 2001. p. 17–44. Vardiman JW, Brunning RD, Harris NL. WHO histological classification of chronic myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, et al., editors. World Health Organization classification of tumors: tumours of the haematopoietic and lymphoid tissues. Lyon: France, International Agency for Research on Cancer Press; 2001. p. 17–44.
15.
Zurück zum Zitat Hussein K, Huang J, Lasho T, Pardanani A, Mesa RA, Williamson CM, et al. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur J Haematol. 2009;82(4):255–9.PubMedCrossRef Hussein K, Huang J, Lasho T, Pardanani A, Mesa RA, Williamson CM, et al. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur J Haematol. 2009;82(4):255–9.PubMedCrossRef
16.
Zurück zum Zitat Shaffer LG, Slovak ML, Campbel LJ. ISCN 2009—An International System for Human Cytogenetic Nomeclature. Basel: S. Karger; 2009. 2009. Shaffer LG, Slovak ML, Campbel LJ. ISCN 2009—An International System for Human Cytogenetic Nomeclature. Basel: S. Karger; 2009. 2009.
17.
Zurück zum Zitat Vannucchi AM. Management of myelofibrosis. Hematology Am Soc Hematol Educ Program. 2011;2011:222–30.PubMedCrossRef Vannucchi AM. Management of myelofibrosis. Hematology Am Soc Hematol Educ Program. 2011;2011:222–30.PubMedCrossRef
18.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4ª ed. Lyon: IARC; 2008. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4ª ed. Lyon: IARC; 2008.
19.
Zurück zum Zitat Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128–32.PubMed Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128–32.PubMed
20.
Zurück zum Zitat Chelloul N, Briere J, Laval-Jeantet M, Najean Y, Vorhauer W, Jacquillat C. Prognosis of myeloid metaplasia with myelofibrosis. Biomedicine. 1976;24(4):272–80.PubMed Chelloul N, Briere J, Laval-Jeantet M, Najean Y, Vorhauer W, Jacquillat C. Prognosis of myeloid metaplasia with myelofibrosis. Biomedicine. 1976;24(4):272–80.PubMed
21.
Zurück zum Zitat Najean Y, Cacchione R, Castro-Malaspina H, Dresch C. Erythrokinetic studies in myelofibrosis: their significance for prognosis. Br J Haematol. 1978;40(2):205–17.PubMedCrossRef Najean Y, Cacchione R, Castro-Malaspina H, Dresch C. Erythrokinetic studies in myelofibrosis: their significance for prognosis. Br J Haematol. 1978;40(2):205–17.PubMedCrossRef
22.
Zurück zum Zitat Njoku OS, Lewis SM, Catovsky D, Gordon-Smith EC. Anaemia in myelofibrosis: its value in prognosis. Br J Haematol. 1983;54(1):79–89.PubMedCrossRef Njoku OS, Lewis SM, Catovsky D, Gordon-Smith EC. Anaemia in myelofibrosis: its value in prognosis. Br J Haematol. 1983;54(1):79–89.PubMedCrossRef
23.
Zurück zum Zitat Varki A, Lottenberg R, Griffith R, Reinhard E. The syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine. 1983;62(6):353–71.PubMedCrossRef Varki A, Lottenberg R, Griffith R, Reinhard E. The syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine. 1983;62(6):353–71.PubMedCrossRef
24.
Zurück zum Zitat Barosi G, Berzuini C, Liberato LN, Costa A, Polino G, Ascari E. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol. 1988;70(4):397–401.PubMedCrossRef Barosi G, Berzuini C, Liberato LN, Costa A, Polino G, Ascari E. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol. 1988;70(4):397–401.PubMedCrossRef
25.
Zurück zum Zitat Pereira A, Bruguera M, Cervantes F, Rozman C. Liver involvement at diagnosis of primary myelofibrosis: a clinicopathological study of twenty-two cases. Eur J Haematol. 1988;40(4):355–61.PubMedCrossRef Pereira A, Bruguera M, Cervantes F, Rozman C. Liver involvement at diagnosis of primary myelofibrosis: a clinicopathological study of twenty-two cases. Eur J Haematol. 1988;40(4):355–61.PubMedCrossRef
26.
Zurück zum Zitat Visani G, Finelli C, Castelli U, Petti MC, Ricci P, Vianelli N, Gianni L, Zuffa E, Aloe Spiriti MA, Latagliata R, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 1990;75(1):4–9.PubMedCrossRef Visani G, Finelli C, Castelli U, Petti MC, Ricci P, Vianelli N, Gianni L, Zuffa E, Aloe Spiriti MA, Latagliata R, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 1990;75(1):4–9.PubMedCrossRef
27.
Zurück zum Zitat Tefferi A, Pardanani A, Gangat N, et al. Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia. 2012;26(6):1439–41.PubMedCrossRef Tefferi A, Pardanani A, Gangat N, et al. Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia. 2012;26(6):1439–41.PubMedCrossRef
Metadaten
Titel
Application of five prognostic survival scores to primary myelofibrosis in 62 Brazilian patients
verfasst von
M. C. Souza
C. A. Rodrigues
M. R. R. Silva
J. Ribeiro
R. Tognon
F. A. Castro
B. P. Simões
E. X. Souto
M. L. Chauffaille
Publikationsdatum
01.06.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0555-2

Weitere Artikel der Ausgabe 2/2013

Medical Oncology 2/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.